Send to:

Choose Destination
See comment in PubMed Commons below
J Immunol Methods. 2014 Jul;409:62-71. doi: 10.1016/j.jim.2014.04.011. Epub 2014 May 4.

Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.

Author information

  • 1Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
  • 2Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States.
  • 3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, United States; Cancer Immunotherapy Consortium of the Cancer Research Institute, United States.
  • 4Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States. Electronic address:


Luminex bead array assays are widely used for rapid biomarker quantification due to the ability to measure up to 100 unique analytes in a single well of a 96-well plate. There has been, however, no comprehensive analysis of variables impacting assay performance, nor development of a standardized proficiency testing program for laboratories performing these assays. To meet this need, the NIH/NIAID and the Cancer Immunotherapy Consortium of the Cancer Research Institute collaborated to develop and implement a Luminex assay proficiency testing program as part of the NIH/NIAID-sponsored External Quality Assurance Program Oversight Laboratory (EQAPOL) at Duke University. The program currently monitors 25 domestic and international sites with two external proficiency panels per year. Each panel includes a de-identified commercial Luminex assay kit with standards to quantify human IFNγ, TNFα, IL-6, IL-10 and IL-2, and a series of recombinant cytokine-spiked human serum samples. All aspects of panel development, testing and shipping are performed under GCLP by EQAPOL support teams. Following development testing, a comprehensive site proficiency scoring system comprised of timeliness, protocol adherence, accuracy and precision was implemented. The overall mean proficiency score across three rounds of testing has remained stable (EP3: 76%, EP4: 75%, EP5: 77%); however, a more detailed analysis of site reported results indicates a significant improvement of intra- (within) and inter- (between) site variation, suggesting that training and remediation for poor performing sites may be having a positive impact on proficiency. Through continued proficiency testing, identification of variables affecting Luminex assay outcomes will strengthen efforts to bring standardization to the field.

Copyright © 2014 Elsevier B.V. All rights reserved.


Cytokines; GCLP; Luminex; Multiplex; Proficiency

[PubMed - indexed for MEDLINE]
[Available on 2015-07-01]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk